American Lung Association Joins Lung Cancer Clinical Trial Call to Action Campaign

Provides Lung Cancer Patients Personalized Information about and Matching for Clinical Trials

WASHINGTON, DC (August 26, 2010)

The American Lung Association is encouraging patients with lung cancer to take charge of their diagnosis and learn about clinical trials through the Lung Cancer Clinical Trial Call to Action campaign.

This service provides personalized education to quickly identify trial options that match each patient’s specific diagnosis, stage, and treatment history.  It is an easy-to-use resource that helps patients discuss with their doctor clinical trials that may be appropriate for them. 

“The American Lung Association is dedicated to the fight against lung cancer and is committed to advancing research and patient care for individuals affected by this disease,” said Susan Rappaport, Vice President of Research & Program Services for the American Lung Association. “Each time a person with lung cancer faces a treatment decision, clinical trials is an option they should know to consider. Our goal is to help ease the burden patients and their families may experience when trying to understand and identify clinical trials available to them.”

“African Americans suffer from lung cancer more than any other population group in the United States, and are more likely to wait longer after diagnosis to receive treatment, to refuse treatment, and to die in the hospital after surgery.  They are also woefully under enrolled in clinical trials,” said William J. Hicks, M.D, expert spokesperson for the American Lung Association report Too Many Cases, Too Many Deaths: Lung Cancer in African Americans. “This initiative is an important opportunity to increase African American’s access to the best available options for care and to ultimately eliminate this health disparity.”

The resources available through the Lung Cancer Clinical Trial Call to Action campaign include a Lung Cancer Clinical Trial Matching Service, which provides personalized education and the quick identification of clinical trial options that match each patient’s diagnosis, stage and treatment history. Patients may access the service by visiting any of the participant organization web sites or by calling the toll-free number (1-800-698-0931) to be matched with a compassionate and informed Clinical Trial Specialist who will guide them through the entire process.

“When treatment is offered or changed for a lung cancer patient, one should discuss with their doctor whether clinical trials may offer the advantage of access to new drugs undergoing testing,” said Norman Edelman, M.D., Chief Medical Officer for the American Lung Association.

The Lung Cancer Clinical Trial Call to Action campaign brings together 11 top lung cancer groups including: the American Lung Association, Bonnie J Addario Lung Cancer Foundation, CancerCare's, Caring Ambassadors Lung Cancer Program, Lung Cancer Alliance, LungCAN, LUNGevity, National Lung Cancer Partnership, Respiratory Health Association of Metropolitan Chicago, The Beverly Fund, and Uniting Against Lung Cancer. EmergingMed is the service provider for the Lung Cancer Clinical Trials Matching Service. The effort is being supported by several major pharmaceutical companies, including Amgen Inc., AstraZeneca, Boehringer Ingelheim, Genentech BioOncology, and Pfizer Oncology, that are all dedicated to the fight against lung cancer.

About Lung Cancer
Lung Cancer is the number one cancer killer of both men and women, and there are currently 365,000 people living with the disease. In 2008, approximately 1.61 million new cases of lung cancer were diagnosed worldwide, with 1.38 million people dying from the disease. In the United States, an estimated 157,300 deaths, accounting for 28 percent of all cancer deaths, occurred in 2010, according to the American Cancer Society.

Lung Cancer Clinical Trial Call to Action Service Provider
EmergingMed was founded in 2000 and since that time has assisted over 120,000 cancer patients with customized searches for clinical trials. EmergingMed’s goal is to increase clinical trial awareness and access through one-on-one, personalized services provided through collaborations with a growing partner network.

For More Information
For background information on clinical trials, including frequently asked questions, go to



About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to improve the air we breathe; to reduce the burden of lung disease on individuals and their families; and to eliminate tobacco use and tobacco-related diseases.  For more information about the American Lung Association, a holder of the Better Business Bureau Wise Giving Guide Seal, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: